Christopher P Day

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Enzo Bonora, E. Bonora, G. Targher, 2010, The New England journal of medicine.

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Giorgio Saracco, Neeraj Bhala, N. Bhala, 2011, Hepatology.

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

Christian Thoma, M. Trenell, C. Day, 2012, Journal of hepatology.

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

G. Aithal, C. Day, J. Leathart, 2007, Gastroenterology.

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease

Timothy Hardy, Q. Anstee, C. Day, 2016, Gut.

Warfarin dose requirement and CYP2C9 polymorphisms

G. Aithal, C. Day, P. Kesteven, 1999, The Lancet.

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

G. Aithal, C. Day, P. Kesteven, 1999, The Lancet.